SENSEX NIFTY
Jul 27, 2013, 01.22 PM IST | Source: Moneycontrol.com

Glenmark, Natco get final US nod for anti-migraine drug

Rizatriptan Benzoate orally disintegrating tablets are a generic version of Merck's Maxalt MLT Tablets.

Moneycontrol Bureau

Glenmark Pharma 's US generics subsidiary and another generics drugs maker Natco Pharma have received final approval from US Food and Drug Administration for Rizatriptan Benzoate orally disintegrating tablets, used to treat migraine headaches.

Both the companies have approval to sell the tablets in 5mg and 10mg strengths.

Rizatriptan ODT is a generic version of Merck's Maxalt MLT tablets and Glenmark said it will start shipping its tablets immediately.

Natco said it has already started shipping the product launched by its marketing partner Breckenridge Pharmaceuticals.

Rizatriptan ODT had sales of USD 263 million for the year ended March 2013, Glenmark said, citing IMS Health data.

Glenmark now has 87 products authorized for distribution in the US market and 53 ANDAs (abbreviated new drug application) are pending approval with the drug regulator.

Glenmark shares ended up about 1 percent at Rs 575.35 on NSE on Tuesday. Natco ended up 1.5 percent at Rs 454.65.

Also Read: RBI names 26 applicants for new banking licence

Nachiket Kelkar
nachiket.kelkar@network18online.com

Glenmark stock price

On July 23, 2014, Glenmark Pharma closed at Rs 591.65, up Rs 17.80, or 3.10 percent. The 52-week high of the share was Rs 640.35 and the 52-week low was Rs 489.10.


The company's trailing 12-month (TTM) EPS was at Rs 15.99 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 37. The latest book value of the company is Rs 107.14 per share. At current value, the price-to-book value of the company is 5.52.

Set email alert for

ADS BY GOOGLE

video of the day

See 8000 Nifty by Dec, bullish energy, cap goods: Religare

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.